Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Cell Therapy
The global cell therapy technologies market is projected to reach USD 5.6 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 14.4% from 2020…
Posted: November 4, 2020 at 5:56 am
New York, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Technologies Market by Product, Process, Cell Type, End User - Global Forecast to 2025" - https://www.reportlinker.com/p05676493/?utm_source=GNW Also, the emergence of iPSCs as an alternative to ESCs and increased focus on personalized medicine to offer an opportunity for the growth of the market during the forecast period.
Consumables is expected to hold the largest share of the cell therapy technologies market, by product in 2020.On the basis of product, the market is segmented into consumables, equipment, and systems & software.The consumables segment accounted for the largest share of the cell therapy technologies market in 2019.
Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.
T-cells is expected to hold the largest share of the cell therapy technologies market, in 2020.On the basis of cell type, the market is segmented into, T-cells, stem cells, and other cells.In 2019, T-cells accounted for the largest share of the cell therapy technologies market.
Favorable government initiatives and the increasing demand for T-cell therapies are the key factors driving the growth of this segment.
Cell processing is expected to hold the largest share of the cell therapy technologies market in 2020.On the basis of process, the market is segmented into cell processing, cell preservation, distribution and handling, and process monitoring and quality control.The cell processing segment dominated the market in 2019.
This segment is expected to grow at the highest CAGR during the forecast period.The cell processing stage makes the highest use of cell therapy instruments and media, especially during culture media processing.
This is the major factor responsible for the large share and high growth of this segment.
Biopharmaceutical & biotechnology companies and CROs segment commanded the largest share of the cell therapy technologies market in 2020By end user, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies and CROs and research institutes and cell banks.Biopharmaceutical & biotechnology companies and CROs dominate the market and are expected to grow at the highest CAGR.
The large share of this regional segment can primarily be attributed to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.
North America commanded the largest share of the cell therapy technologies market in 2020.On the basis of region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, and Rest of the World.In 2019, North America commanded the largest share of the cell therapy technologies market.
The large share of this market segment can be attributed to the increasing incidence of CVD, increasing healthcare expenditure, growing disposable income, growing healthcare awareness, and the availability of technologically advanced devices in the region.
Breakdown of supply-side primary interviews, by company type, designation, and region: By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%) By Designation: C-level (30%), Director-level (20%), and Others (50%) By Region: North America (35%), Europe (24%), AsiaPacific (25%), and RoW (16%).
The some of the major players operating in this market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany) and Danaher Corporation (US).
List of Companies Profiled in the Report Thermo Fisher Scientific Inc. (US) Merck KGaA (Germany) MaxCyte (US) Danaher Corporation (US) Becton, Dickinson and Company (US) Lonza Group (Switzerland) Sartorius AG (Germany) Terumo BCT (US) Fresenius Medical Care AG & Co. KGaA (Germany) Avantor, Inc. (US) Bio-Techne Corporation (US) Corning Incorporated (US) FUJIFILM Irvine Scientific (US) Werum IT Solutions GmbH (Germany) RoosterBio Inc. (US) SIRION Biotech GmbH (Germany) CellGenix GmbH (Germany) L7 Informatics, Inc. (US) Miltenyi Biotec GmbH (Germany) STEMCELL Technologies (Canada) Hemasoft (US) MAK-SYSTEM (US) OrganaBio, LLC (US) IxCells Biotechnology (China) Wilson Wolf Corporation (US)
Research CoverageThis report studies the cell therapy technologies market based on product, cell type, process, end user, and region.The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth.
It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell therapy technologies market.
The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers: Market Penetration: Comprehensive information on cell therapy technologies offered by the top 25 players in the cell therapy technologies market. The report analyzes the cell therapy technologies market by product, cell type, process, end user, and region. Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the cell therapy technologies market
Frequently asked questions What are the growth opportunities in the cell therapy technologies market across major regions in the future? Which type of cells are expected to hold the largest share in the cell therapy technologies market? What are the various cell therapy technologies product types and their respective market shares in the overall market? Which region has a well-developed cell therapy technologies market? What is the impact of COVID-19 on cell therapy technologies market?Read the full report: https://www.reportlinker.com/p05676493/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Follow this link:
The global cell therapy technologies market is projected to reach USD 5.6 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 14.4% from 2020...
Posted in Cell Therapy
Comments Off on The global cell therapy technologies market is projected to reach USD 5.6 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 14.4% from 2020…
Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |…
Posted: November 4, 2020 at 5:56 am
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global autologous cell therapy market and it is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download Latest Free Sample Report on COVID-19 Analysis
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
The use of biomass as a fuel in boilers has been instrumental in driving the growth of the market.
Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Download a Free Sample Report on COVID-19 Impacts
Autologous Cell Therapy Market 2020-2024: Segmentation
Autologous Cell Therapy Market is segmented as below:
Autologous Cell Therapy Market 2020-2024: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The autologous cell therapy market report covers the following areas:
This study identifies the increasing demand for effective drugs for cardiac and degenerative disorders as one of the prime reasons driving the Autologous Cell Therapy Market growth during the next few years.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Autologous Cell Therapy Market 2020-2024: Key Highlights
Table of Contents:
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Therapy
Customer landscape
Geographic Landscape
Drivers, Challenges, and Trends
Vendor Landscape
Vendors covered
Appendix
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Go here to read the rest:
Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |...
Posted in Cell Therapy
Comments Off on Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |…
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy – GlobeNewswire
Posted: November 4, 2020 at 5:56 am
LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics. The trial is being led by Dr. Koen van Besien at Weill Cornell Medical College/New York Presbyterian Hospital. Separately, the FDA has also cleared agenT-797 to treat patients with cancer. Cancer trials are expected to commence shortly.
"We are pleased to advance our proprietary iNKT cell therapy in our efforts to address the COVID-19 pandemic, said Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics. Our trial is designed to treat patients with moderate to severe symptoms of COVID-19, where these cells have the potential to clear SARS-CoV-2 virus, dampen harmful inflammation, and prevent reinfection.
"iNKT cell therapy offers new promise for the fight against solid tumor cancers as well as COVID-19, said Dr. Garo Armen, Chairman and CEO of Agenus. iNKTs can penetrate tissues, giving them a critical advantage in targeting solid tumors not currently served by approved cell therapies. iNKTs have also demonstrated curative potential in preclinical cancer models that are refractory to available therapies. Our product is designed to treat patients affordably and accessibly.
As a subsidiary of Agenus, AgenTus currently has unique access to Agenuss portfolio of checkpoint antibodies and cancer vaccines which allows for optimal combinations with its cell therapies. This gives the company enormous flexibility to develop effective combinations with curative potential for patients with cancer and infectious disease at a significant cost advantage.
About AgenTus Therapeutics, Inc. AgenTus Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough unmodified and modified allogeneic iNKT cells with engineered receptors, such as T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge the human immune system cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations in Lexington, MA and Cambridge, UK. For more information, please visit http://www.agentustherapeutics.com.
About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated commencement of cell therapy clinical trials for cancer and COVID-19 and the expected benefits to be observed in these trials and with these cell therapy treatments generally. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:Agenus Inc.Caroline Bafundo212-994-8209Caroline.Bafundo@agenusbio.com
The rest is here:
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy - GlobeNewswire
Posted in Cell Therapy
Comments Off on Agenus Doses First COVID-19 Patient with iNKT Cell Therapy – GlobeNewswire
Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth – BioSpace
Posted: November 4, 2020 at 5:56 am
Retinal Disorders Treatment Market: Introduction
According to the report, the global retinal disorders treatment market was valued at US$ 9.18 Bn in 2019 and is projected to expand at a CAGR of ~7% from 2020 to 2030. Macular degeneration is of two types: wet age-related macular degeneration and dry age-related macular degeneration. Diabetic retinopathy is one of the common diabetic eye disorders characterized by damaged blood vessels in the retina. Damaged blood vessels and nerves lead to vision impairment, blurring of vision, and eye hemorrhage. If left untreated, it could lead to retinal detachment and blindness. In terms of indication, the global retinal disorders treatment market has been classified into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. The macular degeneration segment has been bifurcated into dry macular degeneration and wet macular degeneration. Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others. In terms of dosage form, the global retinal disorders treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79712
Based on distribution channel, the global retinal disorders treatment market has been segregated into hospital pharmacies, retail pharmacies, and online sales. Rise in prevalence of retinal disorders due to increase in geriatric patient population boosts the growth of the global retinal disorders treatment market. The U.S. dominated the global retinal disorders treatment market in 2019, and the trend is anticipated to continue during the forecast period. Well-established healthcare infrastructure and early adoption of advanced technologies are the factors expected to fuel the growth of the market in the region. Moreover, rise in prevalence of various types of retinal disorder leads to increase in demand for treatment.
China is likely to be a highly lucrative market for retinal disorders treatment during the forecast period. Diagnosis and treatment rates have increased due to a rise in disposable income and health awareness. This has led to an increase in the adoption of macular degeneration drugs
Rise in Prevalence of Retinal Disorders Due to Increase in Geriatric Patient Population to Drive Global Market
Age is a prominent risk factor for age-related macular degeneration. The risk of developing advanced age-related macular degeneration increases from 2% in people aged between 50 and 59 to nearly 30% for those over 75. The prevalence of other retinal disorders was 93 million people with diabetic retinopathy, 21 million people diabetic macular edema and 28 million people with vision-threatening diabetic retinopathy. Increase in R&D activities, rise in the number of patients suffering from diseases, and rapid expansion of healthcare and biopharmaceutical industries in developed and developing countries are projected to boost advancements in therapies in the AMD treatment market during the forecast period. For instance, Lucentis and Eylea accounted for 2.8% of total pharmaceutical sales in Canada in 2017.
Request for Analysis of COVID-19 Impact on Retinal Disorders Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79712
Macular Degeneration to Dominate Global Market
In terms of indication, the global retinal disorders treatment market has been divided into macular degeneration, diabetic retinopathy, diabetic macular edema, and others. Macular degeneration has been bifurcated into dry macular degeneration and wet macular degeneration. The macular degeneration segment dominated the market in terms of revenue in 2019. The rise in prevalence of macular degeneration is anticipated to drive the segment during the forecast period. For instance, the number of people living with macular degeneration is expected to reach 196 million globally by 2020 and increase to 288 million by 2040.
Anti-VEGF Agents to be Main Therapeutic Class
Based on therapeutic class, the global retinal disorders treatment market has been categorized into anti-VEGF agents and others. The anti-VEGF agents dominated the global retinal disorders treatment market in 2019. Major market products such as Avastin and Eylea are included in the anti-VEGF drug class. Increase in demand for these products in the treatment of retinal disorders and strong product pipeline are likely to drive the segment. However, the others segment, which includes anti-inflammatory drugs, is projected to expand at the highest CAGR from 2020 to 2030. The increase in the use of anti-inflammatory drugs for pain relief is anticipated to augment the segment.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79712
Eye Solutions to be Preferred Dosage Form
In terms of dosage form, the global retinal disorders treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye solutions segment dominated the global retinal disorders treatment market in 2019. However, the eye drops segment is expected to expand at the highest CAGR during the forecast period. The segment is likely to grow at a rapid pace due to increase in demand for eye drops for treatment of retinal diseases in emerging countries such have China, India, and Brazil.
Retail Pharmacies to Emerge as Major Distribution Channel
Based on distribution channel, the global retinal disorders treatment market has been segregated into hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment dominated the market in terms of revenue in 2019 due to wide network, ease of access, and diverse product offerings, including prescription and OTC ophthalmic drugs. However, the shift toward the use of electronic payment modes is projected to boost the growth of the online sale segment during the forecast period.
U.S. to Dominate Global Market
The global retinal disorders treatment market has been segmented into five major regions/country: the U.S., Europe, China, Russia, and Rest of the World. The U.S. dominated the global market in 2019, followed by Europe. The U.S. accounted for a major share of the global retinal disorders treatment market in 2019. Well-developed healthcare infrastructure, high healthcare expenditure, and adoption of branded drugs to treat retinal disorder disorders are the key factors attributed to the countrys significant share of the global market.
The retinal disorders treatment market in China is anticipated to expand at a high CAGR from 2020 to 2030. There have been significant unmet medical needs in the region. Furthermore, healthcare expenditure is increasing in developing markets. Key players are making investments to establish their operations in China. This, in turn, is projected to augment the market in the country.
Buy Retinal Disorders Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79712<ype=S
Competition Landscape
Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., and Novartis AG are the three major companies operating in the global retinal disorders treatment market. The global retinal disorders treatment market is fragmented in terms of number of players. Key players in the global market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited. New product development through robust R&D activities and mergers & acquisitions are key strategies adopted by these players to gain a competitive advantage in the global retinal disorders treatment market.
Browse More Trending Reports by Transparency Market Research:
Lumbar Stenosis Treatment Market: https://www.transparencymarketresearch.com/lumbar-stenosis-treatment-market.html
Intracranial Stenosis Treatment Market: https://www.transparencymarketresearch.com/intracranial-stenosis-treatment-market.html
Plastic Bandages Market: https://www.transparencymarketresearch.com/plastic-bandages-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit BhiseyTransparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
See the rest here:
Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth - BioSpace
Posted in Cell Therapy
Comments Off on Retinal Disorders Treatment Market: Advancements in Gene-therapy and Stem-cell Therapy to Bolster Market Growth – BioSpace
Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market – BioSpace
Posted: November 4, 2020 at 5:56 am
Global Cell Banking Outsourcing Market: Overview
The global cell banking outsourcing market is likely to be driven by the rising demand for biopharmaceutical production targeting novel active sites, stem cell therapy, and gene therapy. A cell bank is a facility storing cells extracted from various organ tissue and body fluids so as to cater to the needs of the future. The cell banks make storage of cells with an elaborate characterization of the entire cell line as it reduces the possibilities of cross contamination. These benefits are estimated to fuel expansion of the global cell banking outsourcing market over the timeframe of assessment, from 2020 to 2030.
Read Report Overview - https://www.transparencymarketresearch.com/cell-banking-outsourcing-market.html
Cell banking outsourcing industries engage testing, characterization, storage, and collection of tissues, cell lines, and the cells. These activities are done to assist in the production of biopharmaceuticals and in the research and development activities so as to ensure minimum adverse effects and high effectiveness. The procedure of the cell storage involves first proliferation of cells, which then multiplies in a huge number of identical cells and is then put inside cryovials safety for use in future. Cells are primarily utilized in the production of regenerative medicine. A surge in the number of cell banks together with the high demand for stem cell therapies is likely to work in favor of the global cell banking outsourcing market over the tenure of analysis, from 2020 to2030.
The global cell banking outsourcing market has been segmented on the basis of four important parameters, which are bank type, phase, cell type, and region.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79685
Global Cell Banking Outsourcing Market: Notable Developments
The global cell banking outsourcing market is considered a fairly competitive market and is marked with the presence of many leading market players. The companies in this market are forging mergers, partnerships, and collaborations so as to gain larger revenue and market share. The following development is expected to play an important role in the market:
Request for Analysis of COVID-19 Impact on Cell Banking Outsourcing Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1645
Global Cell Banking Outsourcing Market: Key Trends
The global cell banking outsourcing market is characterized by the presence of the following restraints, drivers, and opportunities.
High Demand for Stem Cell Therapies to Trigger Growth of the Market
The rising number of stem cell therapies across the globe primarily influences the global cell banking outsourcing market. According to a survey conducted by World Network for Blood and Marrow Transplantation (WBMN), nearly 1 million hematopoietic stem cell transplantation processes were conducted in between 2006 to 2014. These figure comprised removal of stem cells procedures from peripheral blood or bone marrow, proliferating, and then finally storing them cell banks for future use by patients. Stem cell therapies are able to multiple disease, such as amyotrophic lateral sclerosis, type 1 diabetes, cancer, Alzheimer's disease, Parkinson's disease, and so on. Ability to cure such a wide variety of diseases is expected to propel growth of the global cell banking outsourcing market in the years to come.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1645
Global Cell Banking Outsourcing Market: Geographical Analysis
North America is expected to dominate the global cell banking outsourcing market throughout the timeframe of analysis, from 2020 to 2030. Such high growth of the North America market is ascribed to the increased production of antibiotics, therapeutics protein, and vaccines. In addition, presence of several biopharmaceutical companies in the region is anticipated to foster growth of the cell banking outsourcing market in North America in the near future.
Pre Book Cell Banking Outsourcing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1645<ype=S
Browse More Trending Reports by Transparency Market Research:
Healthcare Fraud Detection Market: https://www.transparencymarketresearch.com/healthcare-fraud-detection-market.html
Epinephrine Injection Market: https://www.transparencymarketresearch.com/epinephrine-injection-market.html
Dermal Regeneration Matrix Device Market: https://www.transparencymarketresearch.com/dermal-regeneration-matrix-device-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/
Read the original here:
Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market - BioSpace
Posted in Cell Therapy
Comments Off on Cell Banking Outsourcing Market: High Demand for Stem Cell Therapies to Trigger Growth of the Market – BioSpace
Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development – SelectScience
Posted: November 4, 2020 at 5:56 am
Gene and cell therapy expert Dr. Gerhard Bauer explores the powerful therapies that use a patient's own immune cells to treat cancer
In this article, we hear from Dr. Gerhard Bauer, Professor of Hematology-Oncology at the UC Davis Medical Center within the School of Medicine and Director and Designer of the UC Davis Good Manufacturing Practice Facility. Following his earlier research on stem cell gene therapy for HIV and severe combined immune deficiency (SCID), Bauer discusses his current work overseeing the development of life-saving CAR-T cells, highlights how new self-sterilizing instruments have been critical to his teams production of safe gene therapy products for patients, and shares his hopes for the future.
Tell us more about the Good Manufacturing Practice Lab at the UC Davis Institute, and your journey to becoming director
GB: In my early years, I helped operate a laboratory in Vienna testing laboratory blood products for HIV. Until finally, I thought, if I really want to do something about HIV and want to find a treatment or cure for it, then I need to do more than just testing test kits. I was subsequently hired by the University of Maryland at Baltimore to run the HIV laboratory. Whilst there I was able to find a predictor for HIV transmission, from mother to child, which at that time was a cell-based assay designed to predict the transmission rate. From this, we were able to demonstrate that higher viral load leads to more transmission.
I was then asked to move over to the Johns Hopkins University, where I started on the development of stem cell gene therapy for HIV. And then on to Dr. Donald Kohn's laboratory at Children's Hospital Los Angeles, where I was fortunate enough to be able to work on developing all the clinical-grade procedures to transport genes into hematopoietic stem and progenitor cells. This research led to the development of a completely new treatment for ADA-deficient SCID, severe combined immune deficiency.
After the success of the clinical-grade procedures, I was asked to go to Washington University in St. Louis, to build them a completely new Good Manufacturing Practice facility for cell and gene therapy. This was because I had built a GMP facility among the first academic GMP facilities at Children's Hospital Los Angeles. A few years later I moved to California to help build another GMP facility at University of California, Davis, where I am still conducting my research.
The UC Davis Medical Center is a manufacturing facility for cell and gene therapy products that are being used in clinical trials to help treat patients with currently incurable diseases. In this aspect, I overlook all the manufacturing efforts for novel clinical trials. Since 2010, we have been operating very successfully and have a whole pallet of applications, cell and gene therapy, and other applications that we manufacture here.
What are the main goals for your projects using homegrown CAR-T cell therapy approaches?
GB: A very interesting project that we have been tackling is CAR-T cells. Everybody talks about CAR-T cells these days because they have turned from an experimental project into commercialized applications. CAR-T cells are chimeric antigen receptor T cells. They are gene-modified immune cells from the patient. You can take a patient's immune cells, specifically T cells, out in a blood collection procedure, put them into a laboratory, and then insert genes that will produce a completely novel receptor on the cell surface that can recognize cancer cells. Chemotherapy and radiotherapy only kill the fast-growing tumor cells but often a patient will have a relapse. The relapse comes from cells that have survived the chemotherapy or radiation.
The immune system, if properly equipped, allows for the surveillance of all the cancer cells that may still be there even after chemotherapy. With CAR-T cells, we have developed such a weapon that allows the patient's own immune system to recognize the cancer and eliminate it. This can also be sustained elimination because the T cells develop memory T cells that will be reactivated when the cancer comes back.
In my career here at UC Davis, I have been involved in several CAR-T cell projects initiated by biotech companies. Also, another one initiated by UC Davis in collaboration with University of California, San Francisco. And we are manufacturing such CAR-T cells in the laboratory currently and we are initiating investigational new drug applications, INDs, with the FDA to apply these homegrown CAR-T cells as we call them to patients in San Francisco and also here at UC Davis.
What role do incubators play in cell and gene therapy development?
GB: Within a Good Manufacturing Practice laboratory, we need equipment that can be calibrated and that can maintain the operational status in a very precise way, from beginning to end of the process. Also, we must be able to clean these pieces of equipment appropriately. This means we maintain a very clean environment so as not to cross-contaminate or bring any other infections in. It is very important that we get laboratory equipment that can handle all of this.
I have had a good experience with the incubators that we have had over the years in our laboratories. Some had lasted for over 10 years until we replaced them with newer incubators with a unique feature. That feature is a self-sterilizing incubator, which has helped us tremendously in our efforts. We need to keep the time that we work on maintenance of the equipment low because our technicians are needed for making the products. We do not have to do an autoclaving step on the shelves and everything that is in there. We can leave everything in, and it sterilizes itself. It has saved us so much time and effort and our technicians are grateful for that.
Without these incubators, I do not think we would be able to efficiently produce as many products as we do currently. We also must make sure that we produce a safe and efficacious patient product if we do not have reliable incubators, we cannot make reliable products.
What is your vision for the future of gene therapy?
GB: Up to now we have been able to demonstrate that gene therapy is very safe. We have seen so many patients cured with ADA-deficient SCID safely. In CAR-T cell therapy, which is also a gene therapy, we have saved the lives of so many patients safely.
In the future, we need to expand these already working methods. We must make CAR-T cell therapy available for the many people that need it. Often scaling up is not possible because it is an autologous therapy. I would say scale out, not scale up. Scaling out means that you have many different laboratories where you can make these products and each product is being made in an efficient way. We are going to have to develop methods to efficiently manufacture these products side by side. This will be possible with automation.
Hopefully, in a few years down the road, we will be able to provide those who need it with cell and gene therapy. The second thing is that it is likely that genetic diseases will be curable with gene therapy, more of these cures are being worked on currently. Not only is cell therapy involved in that, but gene therapy vectors can also be administered directly into the patient to look for the cells they need to cure, and then illicit the cure directly without having to transplant cells. So, the future is very interesting, and having seen it from the very beginning to where we are now is something that I really enjoy.
More on the impact of PHCbi technology:
Find out more about Dr. Gerhard Bauers research here>>
Do you use PHCbi products in your lab? Write a review today for your chance to win a $400 Amazon gift card>>
Continue reading here:
Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development - SelectScience
Posted in Cell Therapy
Comments Off on Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development – SelectScience
Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia – GlobeNewswire
Posted: November 4, 2020 at 5:56 am
Basel, October 30, 2020 Novartis today announced the receipt of marketing authorization from Japans Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe ("FBRI") to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients in Japan. This approval makes FBRI the first and only approved commercial manufacturing site for CAR-T cell therapy in Asia.
Behind our efforts to reimagine medicine with CAR-T cell therapy lies a commitment to build a manufacturing network that brings treatment closer to patients, commented Steffen Lang, Global Head of Novartis Technical Operations. The expertise and infrastructure of FBRI, a world-leading manufacturing organization, allows us to bring CAR-T manufacturing to Asia. With the Japan MHLW commercial manufacturing approval, the recent capacity expansion in the US and our ongoing efforts to optimize and evolve our processes, we are well-positioned to deliver this potentially curative treatment option to more patients around the world.
Novartis has the largest geographical CAR-T cell therapy manufacturing network in the world, including seven CAR-T manufacturing facilities, across four continents. Commercial manufacturing for Kymriah now takes place at five sites globally including at the Morris Plains, New Jersey facility, where the US Food and Drug Administration (FDA) recently approved a further increase in manufacturing capacity.
Kymriah is the first-ever FDA-approved CAR-T cell therapy, and the first-ever CAR-T to be approved in two distinct indications. It is a one-time treatment designed to empower patients immune systems to fight their cancer. Kymriah is currently approved for the treatment of r/r pediatric and young adult (up to 25 years of age) acute lymphoblastic leukemia (ALL), and r/r adult diffuse large B-cell lymphoma (DLBCL)1. Kymriah, approved in both indications by the Japan MHLW in 2019, is currently the only CAR-T cell therapy approved in Asia. Clinical manufacturing began at FBRI in 2019 and will continue alongside commercial manufacturing.
Kymriah was developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, a strategic alliance between industry and academia, which was first-of-its-kind in CAR-T research and development.
About Novartis Commitment to Oncology Cell & Gene Novartis has a mission to reimagine medicine by bringing curative cell & gene therapies to patients worldwide. Novartis has a deep CAR-T pipeline and ongoing investment in manufacturing and supply chain process improvements. With active research underway to broaden the impact of cell and gene therapy in oncology, Novartis is going deeper in hematological malignancies, reaching patients with other cancer types and evaluating next-generation CAR-T cell therapies that focus on new targets and utilize new technologies.
Novartis was the first pharmaceutical company to significantly invest in pioneering CAR-T research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of Novartis commitment to CAR-T cell therapy. Kymriah is currently approved for use in at least one indication in 26 countries and at more than 260 certified treatment centers, with the ambition for further expansion to help fulfill the ultimate goal of bringing CAR-T cell therapy to every patient in need.
The Novartis global CAR-T manufacturing footprint spans seven facilities, across four continents. This comprehensive, integrated footprint strengthens the flexibility, resilience and sustainability of the Novartis manufacturing and supply chain. Commercial and clinical trial manufacturing is now ongoing at Novartis-owned facilities in Stein, Switzerland, Les Ulis, France and Morris Plains, New Jersey, USA, as well as at the contract manufacturing sites at Fraunhofer-Institut for cell therapy and immunology (Fraunhofer-Institut fr Zelltherapie und Immunologie) facility in Leipzig, Germany, and now FBRI in Kobe, Japan. Manufacturing production at Cell Therapies in Australia and Cellular Biomedicine Group in China is forthcoming.
ImportantSafety information from the Kymriah SmPC
EU Name of the medicinal product:
Kymriah 1.2 x 106 6 x 108 cells dispersion for infusion
Important note: Before prescribing, consult full prescribing information.
Presentation: Cell dispersion for infusion in 1 or more bags for intravenous use (tisagenlecleucel).
Indications: Treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse posttransplant or in second or later relapse. Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Dosage and administration:
B-cell patients: For patients 50 kg and below: 0.2 to 5.0 x 106 CAR-positive viable T-cells/kg body weight. For patients above 50 kg: 0.1 to 2.5 x 108 CAR-positive viable T-cells (non-weight based).
DLBCL Patients: 0.6 to 6.0108 CAR-positive viable T-cells (non-weight based).
Pretreatment conditioning (lymphodepleting chemotherapy): Lymphodepleting chemotherapy is recommended to be administered before Kymriah infusion unless the white blood cell (WBC) count within one week prior to infusion is 1,000 cells/L. The availability of Kymriah must be confirmed prior to starting the lymphodepleting regimen.
Precautions before handling or administering Kymriah: Kymriah contains genetically modified human blood cells. Healthcare professionals handling Kymriah should therefore take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases.
Preparation for infusionThe timing of thaw of Kymriah and infusion should be coordinated. Once Kymriah has been thawed and is at room temperature (20C 25C), it should be infused within 30minutes to maintain maximum product viability, including any interruption during the infusion.
Administration Kymriah should be administered as an intravenous infusion through latexfree intravenous tubing without a leukocyte depleting filter, at approximately 10 to 20mL per minute by gravity flow. If the volume of Kymriah to be administered is 20mL, intravenous push may be used as an alternative method of administration.
All contents of the infusion bag(s) should be infused.
Clinical assessment prior to infusion: Kymriah treatment should be delayed in some patient groups at risk (see Special warnings and precautions for use).
Monitoring after infusion: Patients should be monitored daily for the first 10 days following infusion for signs and symptoms of potential cytokine release syndrome, neurological events and other toxicities. Physicians should consider hospitalisation for the first 10 days post infusion or at the first signs/symptoms of CRS and/or neurological events. After the first 10 days following the infusion, the patient should be monitored at the physicians discretion. Patients should be instructed to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion.
Elderly (above 65 years of age): Safety and efficacy have not been established in B-cell patients. No dose adjustment is required in patients over 65 years of age in DLBCL patients.
Paediatric patients: No formal studies have been performed in paediatric patients with B-cell ALL below 3 years of age. The safety and efficacy of Kymriah in children and adolescents below 18 years of age have not yet been established in DLBCL. No data are available.
Patients seropositive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV): There is no experience with manufacturing Kymriah for patients with a positive test for HIV, active HBV, or active HCV infection. Leukapheresis material from these patients will not be accepted for Kymriah manufacturing.
Contraindications: Hypersensitivity to the active substance or to any of the excipients of Kymriah. Contraindications of the lymphodepleting chemotherapy must be considered.
Warnings and precautions: Reasons to delay treatment: Due to the risks associated with Kymriah treatment, infusion should be delayed if a patient has any of the following conditions: Unresolved serious adverse reactions (especially pulmonary reactions, cardiac reactions or hypotension) from preceding chemotherapies, active uncontrolled infection, active graft versus host disease (GVHD), significant clinical worsening of leukaemia burden or rapid progression of lymphoma following lymphodepleting chemotherapy. Blood, organ, tissue and cell donation: Patients treated with Kymriah should not donate blood, organs, tissues or cells.
Active central nervous system (CNS) leukaemia or lymphoma: There is limited experience of use of Kymriah in patients with active CNS leukaemia and active CNS lymphoma. Therefore the risk/benefit of Kymriah has not been established in these populations. Risk of CRS: Occurred in almost all cases within 1 to 10 days post infusion with a median time to onset of 3 days and a median time to resolution of8 days. See full prescribing information for management algorithm of CRS. Risk of neurological events: Majority of events, in particular encephalopathy, confusional state or delirium, occurred within 8 weeks post infusion and were transient. The median time to onset of neurological events was 8 days in B-cell ALL and 6 days in DLBCL; the median time to resolution was 7 days for B-cell ALL and 13 days for DLBCL. Patients should be monitored for neurological events. Risk of infections: Delay start of therapy with Kymriah until active uncontrolled infections have resolved. As appropriate, administer prophylactic antibiotics and employ surveillance testing prior to and during treatment with Kymriah. Serious infections were observed in patients, some of which were life threatening or fatal. After Kymriah administration observe patient and ensure prompt management in case of signs of infection Risk of febrile neutropenia: Frequently observed after Kymriah infusion, may be concurrent with CRS. Appropriate management necessary. Risk of prolonged cytopenias: Appropriate management necessary. Prolonged cytopenia has been associated with increased risk of infections. Myeloid growth factors, particularly granulocyte macrophage colony stimulating factor (GM CSF), not recommended during the first 3 weeks after Kymriah infusion or until CRS has been resolved. Risk of secondary malignancies: Patients treated with Kymriah may develop secondary malignancies or recurrence of their cancer and should be monitored lifelong for secondary malignancies. Risk of hypogammaglobulinemia or agammaglobulinemia: Infection precautions, antibiotic prophylaxis and immunoglobulin replacement should be managed per age and standard guidelines. In patients with low immunoglobulin levels preemptive measures such as immunoglobulin replacement and rapid attention to signs and symptoms of infection should be implemented. Live vaccines: The safety of immunisation with live viral vaccines during or following Kymriah treatment was not studied. Vaccination with live virus vaccines is not recommended at least 6 weeks prior to the start of lymphodepleting chemotherapy, during Kymriah treatment, and until immune recovery following treatment with Kymriah. Risk of tumor lysis syndrome (TLS): Patients with elevated uric acid or high tumor burden should receive allopurinol or alternative prophylaxis prior to Kymriah infusion. Continued monitoring for TLS following Kymriah administration should also be performed. Concomitant disease: Patients with a history of active CNS disorder or inadequate renal, hepatic, pulmonary or cardiac function are likely to be more vulnerable to the consequences of the adverse reactions of Kymriah and require special attention. Prior stem cell transplantation: Kymriah infusion is not recommended within 4 months of undergoing an allogeneic stem cell transplant (SCT) because of potential risk of worsening GVHD. Leukapheresis for Kymriah manufacturing should be performed at least 12weeks after allogeneic SCT. Serological testing: There is currently no experience with manufacturing Kymriah for patients testing positive for HBV, HCV and HIV. Screening for HBV, HCV and HIV, must be performed before collection of cells for manufacturing. Hepatitis B virus (HBV) reactivation, can occur in patients treated with medicinal products directed against B cells and could result in fulminant hepatitis, hepatic failure and death. Prior treatment with anti CD19 therapy: There is limited experience with Kymriah in patients exposed to prior CD19 directed therapy. Kymriah is not recommended if the patient has relapsed with CD19 negative leukaemia after prior anti-CD19 therapy. Interference with serological testing: Due to limited and short spans of identical genetic information between the lentiviral vector used to create Kymriah and HIV, some commercial HIV nucleic acid tests (NAT) may give a false positive result. Sodium and potassium content: This medicinal product contains 24.3 to 121.5mg sodium per dose, equivalent to 1 to 6% of the WHO recommended maximum daily intake of 2g sodium for an adult. This medicinal product contains potassium, less than 1mmol (39mg) per dose, i.e. essentially potassium free. Content of dextran 40 and dimethyl sulfoxide (DMSO): Contains 11 mg dextran 40 and 82.5 mg dimethyl sulfoxide (DMSO) per mL. Each of these excipients are known to possibly cause anaphylactic reaction following parenteral administration. Patients not previously exposed to dextran and DMSO should be observed closely during the first minutes of the infusion period.
Interaction with other medicinal products and other forms of interaction
Live vaccines: The safety of immunisation with live viral vaccines during or following Kymriah treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during Kymriah treatment, and until immune recovery following treatment with Kymriah.
Fertility, pregnancy and lactation
Women of childbearing potential/Contraception in males and females: Pregnancy status for females of reproductive potential should be verified prior to starting treatment with Kymriah. Consider the need for effective contraception in patients who receive the lymphodepleting chemotherapy. There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with Kymriah.
Pregnancy: There are no data from the use of Kymriah in pregnant women. It is not known whether Kymriah has the potential to be transferred to the foetus via the placenta and could cause foetal toxicity, including B cell lymphocytopenia. Kymriah is not recommended during pregnancy and in women of childbearing potential not using contraception. Pregnant women should be advised on the potential risks to the foetus. Pregnancy after Kymriah therapy should be discussed with the treating physician. Pregnant women who have received Kymriah may have hypogammaglobulinaemia. Assessment of immunoglobulin levels is indicated in newborns of mothers treated with Kymriah.
Breast feeding: It is unknown whether Kymriah cells are excreted in human milk, a risk to the breast fed infant cannot be excluded. Women who are breast feeding should be advised of the potential risk to the breast fed infant. Breast-feeding should be discussed with the treating physician.
Fertility: There are no data on the effect of Kymriah on fertility.
Effects on ability to drive and use machinesDriving and engaging in hazardous activities in the 8 weeks following infusion should be refrained due to risks for altered or decreased consciousness or coordination.
Adverse drug reactions:
B-Cell ALL patients and DLBCL patients:
Very common (10%): Infections - pathogen unspecified, viral infections, bacterial infections, fungal infections, anaemia, haemorrhage, febrile neutropenia, neutropenia, thrombocytopenia, cytokine release syndrome, hypogammaglobulinaemia, decreased appetite, hypokalaemia, hypophosphataemia, hypomagnesaemia, hypocalcaemia, anxiety, delirium, sleep disorder, headache, encephalopathy, arrhythmia, hypotension, hypertension, cough, dyspnoea, hypoxia, diarrhoea, nausea, vomiting, constipation, abdominal pain, rash, arthralgia, acute kidney injury, pyrexia, fatigue, oedema, pain, chills, lymphocyte count decreased, white blood cell count decreased, haemoglobin decreased, neutrophil count decreased, platelet count decreased, aspartate aminotransferase increased.
Common (1 to 10%): Haemophagocytic lymphohistiocytosis, leukopenia, pancytopenia, coagulopathy, lymphopenia, infusion-related reactions, graft versus host disease, hypoalbuminaemia, hyperglycaemia, hyponatraemia, hyperuricaemia, fluid overload, hypercalcemia, tumor lysis syndrome, hyperkalaemia, hyperphosphataemia, hypernatraemia, hypermagnesaemia, dizziness, peripheral neuropathy, tremor, motor dysfunction, seizure, speech disorder, neuralgia, ataxia, visual impairment, cardiac failure, cardiac arrest, thrombosis, capillary leak syndrome, oropharyngeal pain, pulmonary oedema, nasal congestion, pleural effusion, tachypnea, acute respiratory distress syndrome, stomatitis, abdominal distension, dry mouth, ascites, hyperbilirubinaemia, pruritus, erythema, hyperhidrosis, night sweats, back pain, myalgia, muscolosceletal pain, influenza-like illness, asthenia, multiple organ dysfunction syndrome, alanine aminotransferase increased, blood bilirubin increased, weight decreased, serum ferritin increased, blood fibrinogen decreased, international normalized ratio increased, fibrin D dimer increased, activated partial thromboplastin time prolonged, blood alkaline phosphate increased, prothrombin time prolonged.
Uncommon: B-cell aplasia, ischaemic cerebral infarction, flushing, lung infiltration.
Packs and prices: Country-specific.
Legal classification: Country-specific.
DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About NovartisNovartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnewsFor Novartis multimedia content, please visithttps://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com
References
1.Kymriah (tisagenlecleucel) Summary of Product Characteristics (SmPC), 2018.
# # #
Novartis Media RelationsE-mail: media.relations@novartis.com
Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com
Continue reading here:
Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire
Posted in Cell Therapy
Comments Off on Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia – GlobeNewswire
BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies – BioBuzz
Posted: November 4, 2020 at 5:56 am
Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.
The Strengths of our Region: Cutting Edge Therapies panel, which was moderated by Mark Cobbold, vice president of Discovery in Early Oncology at AstraZeneca, brought together leaders from three other companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic. Cobbold touted the work performed by the three companies joining him on the panel, Cartesian Therapeutics, Adaptive Phage Therapeutics, and Ziel Bio. Pointing to the work being done by those three companies and AstraZeneca, Cobbold said they are representative of why the BioHealth Capital Region has become one of the most successful BioHubs in the United States.
Youre really pushing the boundaries of whats possible in treating patients, Cobbold told the panelists.
Murat Kalayoglu, Founder, President and Chief Executive Officer of Gaithersburg, Md.-based Cartesian Therapeutics, noted his companys attempts to develop CAR-T treatments for autoimmune diseases, a first-of-its-kind attempt, as well as for respiratory diseases, including acute respiratory distress syndrome, which is associated with COVID-19. Kalayoglu said the concept for the ARDS CAR-T program went from concept to the clinic in a matter of about seven months, making it the first engineered cell therapy in respiratory disease. He said that would not have happened had the company not been flexible in its attempts to combat COVID-19.
Over the past few years, CAR-T treatments have become promising therapies for some hematological cancers, however, they come with a certain safety risk due to toxicity issues. Kalayoglu said Cartesians assets have been engineered with a predictable half-life in order to mitigate those concerns. Because of increased safety, Cartesians RNA-based programs have the potential to become front-line treatments for some diseases.
Unlike many companies, Charlottesville, Va.-based Ziel Bio did not pivot its pipeline to combat COVID-19. Instead, the company remained focused on its core mission of developing treatments for cancer, particularly a monoclonal antibody against cell surface plectin, a target that is highly expressed on the plasma membrane of multiple types of cancer cells. Kimberly Kelly, President and Chief Scientific Officer of Ziel Bio, said the company has been preparing to take that monoclonal antibody, ZB131, into the clinic in 2021. Kelly said cell surface plectin plays a key role in proliferation, migration, and cell survival and as such, has a significant potential as a drug target for a range of difficult to treat cancers.
Ziel is primarily using funds from a $25 million Series A financing round last year to drive the development of that product, as well as other oncology assets that are in the discovery phase. Having additional assets in development is important because that will help the company grow, she said.
Greg Merrill, CEO of Adaptive Phage Therapeutics, also based in Gaithersburg, Md., said breakthroughs in genomics have boosted his companys ability to use phage therapy with fewer complications in order to better address multi-drug resistant infectious diseases. The company has been able to harness its expanding phage library, known as PhageBank, which was originally developed by the U.S. Department of Defense. The company is preparing to begin a Phase I/II study of a phage therapy in conjunction with antibiotics for patients with culture-proven chronic prosthetic joint infection who are candidates for two-stage exchange arthroplasty.
In addition to that movement in its pipeline, Merrill said the company is working with the Department of Defense to develop a phage-based COVID-19 vaccine program. He said the use of phage in humans is well-understood and has the potential to address the growing concern of drug-resistant infections. Merrill added the company has been harnessing the power of machine learning to predict an earlier stage where a particular phage can be effective against a particular bacteria and to predict which phage could be effective based on genomics of a bacterial infection.
While these companies are blazing trails in the BioHealth Capital Region, there are some challenges, particularly in the lack of wet-lab space and less involvement from venture capitalists than in other regions, such as the greater Boston area. While those may currently be lacking, for the most part, the region is filled with strengths, particularly the ability to attract top personnel. Cobbold suggested that the work conducted by biopharma and life science companies in the area is cutting edge, which makes it easier for people to relocate to the area.
Its a magnet for them, he said.
Looking ahead, each of the company representatives suggested that 2021 will bring about multiple milestones, including advancement in clinical development, as well as company growth. Replays of the 6th Annual BioHealth Capital Region forum are available online by visiting https://eventmobi.com/biohealth2020.
Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.
See more here:
BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies - BioBuzz
Posted in Cell Therapy
Comments Off on BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies – BioBuzz
Making Progress Against Relapsed/ Refractory DLBCL Without CAR T – OncLive
Posted: November 4, 2020 at 5:56 am
Approximately of patients with diffuse large B-cell lymphoma (DLBCL) experience refractory disease after initial treatment or have a relapse after achieving remission.1 Until the advent of chimeric antigen receptor (CAR) T-cell therapies, treatment options for these patients had been mostly palliative, especially for those ineligible for autologous stem-cell transplantation (ASCT) and those who relapsed after ASCT. Although CAR T-cell therapies have revolutionized the treatment landscape for relapsed/refractory (R/R) DLBCL, not all patients are candidates for this treatment. Of those who do receive it, 30% to 35% experience long-term benefit, demonstrating a great unmet need for others in the treatment landscape.
Emerging agents have started to shake up the R/R DLBCL armamentarium, but there is still a long road ahead to fully define their role. During an OncLive Peer Exchange, a panel of lymphoma experts discussed several novel agents for R/R DLBCL, some of which have been recently approved. They examined the clinical trial data, discussed how these agents compare with CAR T-cell therapy, and provided insights on how they might be used in clinical practice. Before long, well need more sophistication in how we approach patients, moderator John P. Leonard, MD, said. Hopefully, that means well be using treatments more effectively and have more tools at our disposal.
Tafasitamab-cxix (Monjuvi) is a humanized anti-CD19 monoclonal antibody that has been mostly studied as a combination therapy, particularly with lenalidomide (Revlimid). On July 31, 2020, the FDA granted accelerated approval to the combination for adult patients with R/R DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for ASCT.2
The Fc portion has been enhanced to increase ADCC [antibody-dependent cell-mediated cytotoxicity] and ADCP [antibody-dependent cellular phagocytosis], Kami J. Maddocks, MD, said. She noted that investigators initially examined tafasitamab in a single-arm study as monotherapy in patients with R/R non-Hodgkin lymphoma, the data from which demonstrated responses in DLBCL, including a few complete responses (CRs). In this phase 2a study (NCT01685008), investigators observed responses in 9 of the 35 patients (26%) with DLBCL (2 CRs and 7 partial responses [PRs]), with a median duration of response of 20.1 months (range, 1.1-26.5).3 [This study] signaled that there might be some activity with this agent in large cell lymphoma, Maddocks said. She proceeded to explain that the rationale for combining this agent with lenalidomide is that lenalidomide activates natural killer cells, thereby optimizing the tumor environment for tafasitamab.
Data from L-MIND (NCT02399085) provided the basis for the approval of tafasitamab in combination with lenalidomide. The phase 2, open label, multicenter, single-arm trial included 71 patients with DLBCL who received tafasitamab 12 mg/kg intravenously (days 1, 8, 15 and 22 of each 28-day cycle for 3 cycles, then days 1 and 15 only) with lenalidomide 25 mg orally (days 1-21) for a maximum of 12 cycles, followed by biweekly tafasitamab as monotherapy.4 It was really targeted at those patients who relapsed after their initial therapy or maybe received a first salvage and then were not candidates for ASCT, she said. All patients in the study had previously received 1 to 4 systemic regimens, at least 1 of which was an anti-CD20 therapy.4
Maddocks noted that the combination was well tolerated and that the adverse effects (AEs) were in line with expected AEs for lenalidomide monotherapy. The most common grade 3 or higher treatment-emergent AEs were hematologic abnormalities, including neutropenia (48%), thrombocytopenia (17%), and febrile neutropenia (12%).4 There were very few infusion-related reactions. Approximately three-quarters of the patients were able to stay on lenalidomide 20 mg or higher, Maddocks said.
Tafasitamab/Lenalidomide vs CAR T-Cell Therapy
The panelists proceeded to discuss tafasitamab plus lenalidomide in the context of CAR T-cell therapy and when it might be most useful. They noted that the patients in the L-MIND trial were not heavily pretreated, were not refractory to their first-line treatment, and did not have more aggressive disease subtypes, such as double- or triple-hit biology.
Subsequently, this population was different from those included in the CAR T-cell studies, such as ZUMA-1 (NCT02348216), JULIET (NCT02445248), and TRANSCEND-NHL-001 (NCT02631044), in which 77%, 54%, and 67% of patients, respectively, had primary refractoriness, and 69%, 51%, and 50% received more than 3 lines of therapy.5 Further, in reported data from the JULIET and TRANSCEND-NHL-001 studies, 27% and 22% of patients had double-hit lymphoma, respectively. [CAR T-cell therapy] doesnt care that youre a double-hit. You can still respond and have durability. Its the same thing if youre primary refractory, Matthew Lunning, DO, said. Thus far, there are no data to clarify whether this is also the case for tafasitamab plus lenalidomide.
It is also unknown whether tafasitamab plus lenalidomide can be used as a bridge to CAR T-cell therapy. National Comprehensive Cancer Network guidelines state, It is unclear if tafasitamab will have a negative impact on the efficacy of subsequent anti-CD19 CAR T-cell therapy.6 Lunning said that preclinical data have shown that there is no negative affect with tafasitamab.
[Cell line studies show] that it does engage the same CD19 antigen that youd expect the CAR T cell to go after but, at least in cell lines, it did not appear to affect the CAR T cells, he said. Maddocks added that there was 1 patient enrolled in the L-MIND trial who received CAR T-cell therapy after progression on tafasitamab plus lenalidomide and who has been in remission for more than a year. However, she warned that you cannot draw conclusions based on 1 patient. As this combination becomes available to people, well hopefully know more about whether there is an effect on the efficacy of CAR T, she said.
Despite the unknown effect of tafasitamab plus lenalidomide as a bridging therapy to CAR T, the panelists agreed this may be a reasonable use. If it takes a couple of weeks to get patients to their apheresis and then another 3 weeks to get them [to delivery], maybe tafasitamab is the best option. Its 8 weekly doses early on and youre getting drug exposure with the intent to go to CAR T-cell therapy or a patient could say no, and you havent lost anything if theyre responding, Lunning said.
Lunning suspects tafasitamab plus lenalidomide will get a lot of use because it is an IV [intravenous] therapy, given weekly for a lot of doses up front, and lenalidomide is an oral therapy that people are very comfortable using in lymphoma and multiple myeloma. Subsequently, he emphasized the importance of capturing the data for those patients previously exposed to tafasitamab/lenalidomide who do not respond or who get a PR and go on to CAR T-cell therapy to determine the true durability of the combination. Thats only going to come out with real-world experience data rather than a commercially funded experience, Lunning said.
The FDA granted selinexor (Xpovio) accelerated approval on June 22, 2020, as a single agent for adult patients with R/R DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.7 The oral agent represents a whole new class of drugs. Its unlike anything that we have for large cell lymphoma or any other cancers. Its called a SINE [selective inhibitor of nuclear export] and it targets certain proteins that are exported out of the nucleus that give cells a prosurvival advantage. It is not necessarily specific to large cell lymphoma, but it targets the mechanism that large cell lymphoma probably uses to keep itself alive and potentially resistant, Nathan H. Fowler, MD, said.
The drugs approval was based on data from SADAL (NCT02227251), a multicenter, single-arm, open-label phase 2b trial in which 134 patients received selinexor 60 mg orally on days 1 and 3 of each week. All patients in the study had previously received 2 to 5 systemic regimens. Thirty-nine patients (29%) responded, with 18 (13%) achieving a CR and 21 (16%) achieving a PR.8 Unlike the L-MIND study, SADAL included patients with double- or triple-expressor status and data showed responses in these patients. If you think about [selinexor in the context of] CAR T-cell data and others, its not quite as good, but its a single drug so its fairly easy to give. It is effective in a subset of patients with large cell lymphoma that is pretty difficult to treat, including patients who have double-hit lymphoma, Fowler said. He also noted that responses appear durable. If you look at patients who have PR or better, the duration of response is over 2 years, [so] there is a select group of patients who do achieve durable benefit with the drug, he explained.
A challenge with selinexor is its toxicity. The most common grade 3 and 4 AEs observed in the SADAL study included thrombocytopenia (49% and 18%, respectively), neutropenia (21% and 9%), fatigue (grade 3/4, 15%), and nausea (grade 3/4, 6%).7 Maddocks said that in her experience gastrointestinal toxicity was most problematic but once this was addressed with antiemetics, it became less concerning. The FDA recommends that selinexor be administered with antiemetic prophylaxis.7
The panelists emphasized that selinexor is not a replacement for CAR T-cell therapy but added that it may help fill an unmet need for patients who have limited treatment options. For patients who are failing [ASCT or CAR T], we dont have a lot of options. We can do lenalidomide and lenalidomide plus a CD19-targeted agent. Patients who fail CAR T-cell therapy, those who would not qualify [for CAR T], and those who are not near a [CAR T] center are the obvious population [for selinexor], Fowler said. Maddocks and Lunning agreed.
The panelists noted that many other agents are in clinical trials for R/R DLBCL, including bispecific antibodies such as glofitamab and epcoritamab. [These are] going to be generating data but not a lot of data will follow [treatment with] CAR T, Lunning said. Nevertheless, he is excited to see what kind of durability these drugs will ultimately show. In contrast, another investigational bispecific antibody, mosunetuzumab, has shown favorable efficacy in a phase 1/1b study that included patients with heavily pretreated R/R DLBCL, including those with disease progression after CAR T-cell therapy. Of the 7 evaluable patients with DLBCL who received prior CAR T-cell therapy, 2 achieved a CR.9
When we were looking at the BiTE [bispecific T-cell engager] molecules a couple of years ago, there was some sense that they would maybe displace CAR Ts. But a lot of the data that were seeing now are immature. I dont think the durable CR rate appears to be at the same level that were seeing with CAR T, at least in large cell lymphoma. So, I dont see these replacing CAR T-cell therapy, but I agree with Drs Maddocks and Lunning that they will probably follow CAR T as a salvage for these patients, Fowler said.
The other treatment the panelists discussed were anti-CD19 antibody-drug conjugates (ADCs). There are 3 CD19 ADCs that have been developed, all showing pretty similar responses; however, 2 are no longer being developed due to toxicity, Maddocks said. She remarked that the third ADC had good initial responses but they were not durable. Subsequently, she noted this agent would probably have to be used as part of a combination therapy to achieve good remissions.
A major challenge in treating DLBCL is that there are no biological markers to guide treatment decision-making. We really need to define the biology by some assay and then use that to put patients into different treatment groups. Thats the holy grail because a one-size-fits-all approach can only move the bar so much in large cell lymphoma, Fowler said.
Its great that were getting all of these new drug classesmore drugs to have the discussions about, Lunning said. Its a chess match against large cell lymphoma and its important to know what piece to play next. You may be moving 1 piece to make a move 3 turns down the road.
References
1. Skrabek P, Assouline S, Christofides A, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;26(4):253-265. doi:10.3747/co.26.5421
2. FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. FDA. Updated August 3, 2020. Accessed October 9, 2020. https://bit.ly/3nmOT43
3. Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkins lymphoma. Ann Oncol. 2018;29(5):1266-1272. doi:10.1093/annonc/mdy056
4. Monjuvi. Prescribing information. MorphoSys US Inc; 2020. Accessed October 9, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf
5. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581. doi:10.1177/2040620719841581
6. NCCN. Clinical Practice Guidelines in Oncology. B-cell lymphomas, version 4.2020. Accessed October 9, 2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
7. FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma. FDA. June 22, 2020. Accessed October 9, 2020. https://bit.ly/36Am12o
8. Xpovio. Prescribing information. Karyopharm Therapeutics Inc; 2020. Accessed October 9, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s001lbl.pdf
9. Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(suppl 1):6. doi:10.1182/blood-2019-123742
Originally posted here:
Making Progress Against Relapsed/ Refractory DLBCL Without CAR T - OncLive
Posted in Cell Therapy
Comments Off on Making Progress Against Relapsed/ Refractory DLBCL Without CAR T – OncLive
Cell Therapy Market Report: Price, New Entrants SWOT Analysis, Competitive Landscape and Gross Margin Forecasted by 2027 – KYT24
Posted: November 4, 2020 at 5:56 am
The latest market report published by Reports and Data, titled Global Cell Therapy Market, presents an accurate analysis of the estimated market size, share, revenue, and sales & distribution networks of the global Cell Therapy market over the forecast period. The report offers an exhaustive overview of the market, along with a precise summary of the markets leading regions. Our team of analysts has studied the existing competitive landscape of the market inside out, focusing on the leading companies and their business expansion strategies. The report ends with conclusive data offering useful insights into the market growth on both regional and global levels.
The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:
JCR Pharmaceuticals Co. Ltd., Fibrocell Science, Inc., Kolon TissueGene, Inc., Osiris Therapeutics, Inc., PHARMICELL Co., Ltd., MEDIPOST, Stemedica Cell Technologies, Inc.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3269
The report draws the focus of the reader on the grave impact of the ongoing COVID-19 pandemic on the Cell Therapy industry and its vital segments and sub-segments. It elaborates on the adverse effects of the pandemic on the global economic scenario, as well as this particular business sphere. The report takes into account the key influencing factors influencing market performance in the present COVID-19 times. The market has been substantially affected by the pandemic, and significant changes have been observed in the market dynamics and demand trends. The report examines the major financial difficulties brought about by the pandemic and offers a future COVID-19 impact assessment.
The market intelligence study takes the reader through the key parameters of the Cell Therapy market, including the strengths and weaknesses of the leading players, using analytical tools like the SWOT analysis and Porters Five Forces analysis. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players.
In market segmentation by types of Cell Therapy, the report covers-
Therapy Type
Therapeutic Area
Cell Type
In market segmentation by applications of the Cell Therapy, the report covers the following uses-
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3269
The investigative study further assesses the market on the basis of market reach and consumer base in the key geographical segments. Alongside reviewing the sales network, distribution channels, pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market, the report studies several factors affecting market growth over the forecast period, such as drivers, restraints, limitations, growth prospects, and numerous macro- and micro-economic indicators.
Key Geographies Encompassed in the Report:
Key questions addressed in the report:
To read more about the report, visit @ https://www.reportsanddata.com/report-detail/cell-therapy-market
Thank you for reading our report. For further queries regarding the report, please get in touch with us. Our team will ensure your report is customized as per your requirements.
About Us:
Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.
Contact Us:
John Watson
Head of Business Development
Reports and Data|Web:www.reportsanddata.com
Direct Line:+1-212-710-1370
E-mail:[emailprotected]
Go here to see the original:
Cell Therapy Market Report: Price, New Entrants SWOT Analysis, Competitive Landscape and Gross Margin Forecasted by 2027 - KYT24
Posted in Cell Therapy
Comments Off on Cell Therapy Market Report: Price, New Entrants SWOT Analysis, Competitive Landscape and Gross Margin Forecasted by 2027 – KYT24